Os 213 melhores médicos do mundo para o tratamento de cancro da próstata

O Dr. Muhammed Mustafa Atci é professor associado de Oncologia Médica no Liv Hospital Topkapı. Especializa-se no tratamento de cancros do cólon, mama, gástrico e pulmão. Anteriormente, serviu como Coordenador de Educação no Hospital Municipal Prof. Dr. Cemil Taşcıoğlu. O Dr. Atci é membro da Sociedade Americana de Oncologia Clínica (ASCO).

• Autor de 19 artigos revistos por pares sobre cancros gastrointestinais, torácicos e endócrinos.
• Publicou estudos sobre resultados de sobrevivência para cancro do cólon em estádio IIB no Journal of Chemotherapy.
• Investiga biomarcadores prognósticos usando exames PET/CT e volume tumoral metabólico.
• Trata casos oncológicos complexos na clínica universitária İstinye University.

O Dr. Ozden traz mais de _doctor_10151_ anos de experiência médica, especializando-se no tratamento do cancro da próstata no hospital VM Medical Park Pendik.

• Graduado pela prestigiada Faculdade de Medicina Cerrahpaşa da Universidade de Istambul
• Completou a subespecialidade em oncologia médica na Universidade de Kocaeli
• Extensa experiência em medicina interna antes de se focar na oncologia

Especialista em terapias oncológicas direcionadas e imunoterapia no complexo hospitalar Medical Park Antalya.

• Mais de 27 anos de experiência em oncologia médica
• Formado nos EUA no Departamento de Oncologia Médica da Universidade de Akdeniz
• Especialista em pesquisa genética de próxima geração para tratamento de câncer
• Professor associado na Faculdade de Medicina da Universidade de Akdeniz

O Dr. Alemdar traz mais de _doctor_9570_ anos de experiência médica, especializando-se no tratamento do cancro da próstata no complexo hospitalar Medical Park Antalya.

• Certificado em Oncologia Médica com formação dedicada na Universidade de Akdeniz
• Vasta experiência em hospitais universitários e estatais na Turquia
• Especialista nos protocolos mais recentes de tratamento do cancro da próstata
• Foca-se em planos de tratamento personalizados adaptados às necessidades de cada paciente

O Dr. Elkhan Mammadov é oncologista clínico. Concentra-se no diagnóstico e tratamento do cancro, incluindo quimioterapia citotóxica, hormonoterapia, terapia direcionada (fármacos inteligentes) e imunoterapia.

Educação: Universidade Médica do Azerbaijão, MD (2004–2010). Universidade de Istambul, Faculdade de Medicina de Istambul, formação em Medicina Interna (2014–2019). Hospital Universitário Istanbul Medipol Mega, formação de subespecialidade em Oncologia Clínica (2019–2022).

Experiência: 5 anos em Medicina Interna. 3 anos em Oncologia Clínica.

Afiliações: Sociedade Turca de Oncologia Clínica. ESMO (Sociedade Europeia de Oncologia Clínica). ASCO (Sociedade Americana de Oncologia Clínica).

O Dr. Lee Chunyong é urologista com doutorado em Medicina pela Faculdade de Medicina da Universidade de Hanyang. O seu foco clínico inclui cálculos renais e urinários (ESWL), doenças da próstata (HPB, cancro da próstata, prostatite), disfunção sexual, vasectomia, cistite, incontinência urinária e disfunção miccional.

Exerceu o cargo de Diretor do Hospital Universitário de Hanyang. Foi presidente e professor titular do Departamento de Urologia da Faculdade de Medicina da Universidade de Hanyang. Foi presidente e, posteriormente, presidente honorário da Sociedade Coreana de Endourologia. Foi também membro do conselho da Société Internationale d'Urologie.

As suas funções internacionais incluem investigador convidado na UCLA e professor convidado na Universidade de Tubinga. Participou duas vezes no programa "Best Doctors" da EBS, abordando doenças da próstata e cálculos renais e urinários.

O Professor Zheng Qiu Hong é Diretor do Centro de Pesquisa em Terapia Celular e um especialista nacional sênior em bioterapia. Ele é professor e supervisor de mestrado na Universidade Médica de Fujian. Possui mais de 30 anos de experiência clínica em biologia molecular tumoral e bioterapia. De 2012 a 2013, foi pesquisador visitante em pesquisa com células-tronco na Escola de Ciências da Vida da Universidade de Connecticut. Anteriormente, ocupou cargos de liderança no Hospital de Câncer de Fujian, incluindo diretor do Laboratório de Biologia Molecular Tumoral e diretor do Laboratório de Pesquisa em Oncologia Cirúrgica. Também atuou como vice-diretor do Laboratório Chave de Bioterapia Tumoral de Fujian e vice-diretor do Centro de Bioterapia e Imunoterapia.

Suas nomeações incluem ser membro do Comitê Permanente do Comitê de Bioterapia da Associação Chinesa de Hospitais de Pesquisa. Ele também é membro do Comitê de Imunologia Tumoral e Bioterapia da Sociedade Chinesa de Imunologia. Além disso, é vice-presidente do Comitê Acadêmico do Centro de Pesquisa em Terapia Celular de Xiamen no Primeiro Hospital Afiliado da Universidade de Xiamen.

Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.

His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.

He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

O médico é um especialista experiente em radiologia intervencionista, com um foco clínico dedicado à imagiologia e intervenções da tiroide e da próstata. Com uma base académica sólida da Faculdade de Medicina da Universidade de Istambul Cerrahpaşa e uma formação de residência especializada em radiologia no Hospital de Formação e Investigação S.B. Haydarpaşa Numune, o médico traz uma vasta experiência para a área.

Ao longo de uma carreira distinta, o médico contribuiu para a prática clínica em instituições como o Hospital da Universidade Başkent de Istambul e o Hospital de Formação e Investigação S.B. Haydarpaşa Numune. Além disso, o médico possui formação em gestão de saúde pela Universidade de Anadolu e mantém membros profissionais ativos na Câmara Médica de Istambul e na Sociedade de Radiologia de Istambul.

O Prof. Jakub Dobruch, MD, PhD, é urologista e cirurgião robótico. É professor de Urologia e chefe do Departamento de Urologia no CMKP (desde 2015). Atua como vice-presidente da Associação Urológica Polonesa (2022–2026). Tornou-se professor de Ciências Médicas em 2021 e professor do CMKP em 2019. Obteve a habilitação em 2014 e o título de especialista em urologia em 2008.

Foco clínico: cirurgia minimamente invasiva e robótica para câncer de próstata, bexiga e rim. Trabalha como cirurgião laparoscópico independente desde 2005. Realiza reconstruções endoscópicas combinadas. Treinou em centros de referência em Nova York, Berlim, Leipzig, Salzburgo, Miami, Dallas e Winston-Salem.

A pesquisa concentra-se em oncologia urológica, especialmente câncer de bexiga e próstata. Liderou projetos financiados pelo CMKP e KBN. É membro dos Jovens Urologistas Acadêmicos da EAU e supervisiona projetos sobre câncer de bexiga. Sua habilitação concentrou-se nas margens cirúrgicas após prostatectomia radical.

O Dr. Vladimir Yutkin traz mais de 30 anos de experiência médica para a sua prática no Hadassah Medical Center.

• Graduado pela Faculdade de Medicina da Universidade Hebraica de Jerusalém
• Especializado no diagnóstico e tratamento de distúrbios da articulação temporomandibular
• Fluente em inglês, hebraico e russo para comunicação com pacientes

O Dr. Joseba Rebollo Liceaga traz mais de _doctor_9719_ anos de liderança em oncologia, incluindo a chefia de departamentos em grandes hospitais na Espanha.

• Especialista em Oncologia Médica pela Clínica Universidad de Navarra
• Liderou departamentos de oncologia em vários hospitais espanhóis de referência
• Publicou pesquisas sobre tratamentos inovadores como a eletroquimioterapia
• Formado na prestigiada Universidade de Navarra
• A sua prática atual foca-se no tratamento integral do cancro

O Dr. Erkan Göcen é especialista em Oncologia Radioterápica no Hospital Privado Çerkezköy Optimed (Optimed Health Group). Formou-se na Universidade de Istambul, Faculdade de Medicina (Çapa), em 2003.

Carreira: Treinou e praticou em Oncologia Radioterápica de 2010 a 2012. Trabalhou em instituições de saúde públicas e privadas de 2012 a 2016. Trabalhou no setor médico privado como especialista em Oncologia Radioterápica de 2016 a 2023. Está no Hospital Optimed desde 2024.

Interesses clínicos: cânceres de cérebro, cabeça e pescoço, esôfago, estômago, colorretal, pâncreas, próstata, bexiga, pulmão, tecidos moles (sarcomas), pele, útero e colo do útero, e mama. Afiliações: Sociedade Turca de Oncologia Radioterápica (TROD) e Câmara Médica de Tekirdağ. Idiomas: inglês e turco.

A Dra. Zalmanova especializa-se em radioterapia para o cancro da próstata no Centro Médico Assuta.

• Radioterapeuta com foco em tratamentos para o cancro da próstata
• Trabalha no Centro Médico Assuta, uma instituição líder em Israel
• Dedicada a planos de tratamento personalizados para cada paciente

O Professor Gofrit lidera o Departamento de Urologia no Hadassah Medical Center e é qualificado em cirurgia robótica. Concluiu formação especializada em urologia invasiva e oncologia no Hospital Universitário de Chicago.

• Médico-chefe de Urologia no Hadassah Medical Center
• Especializado no tratamento cirúrgico do cancro da bexiga e da próstata
• Qualificado para realizar cirurgias robóticas utilizando o sistema da Vinci
• Ensina cirurgia urológica na Universidade Hebraica
• Publicou numerosos artigos científicos sobre urologia e oncologia

Especialista em radioterapia no Rambam Medical Center, com foco no tratamento do câncer de próstata.

• Especializado em radioterapia para câncer de próstata
• Trabalha em um centro médico líder em Israel
• Oncologista com foco no planejamento preciso do tratamento

O Dr. Zohar Dotan chefia o Departamento de Urologia do Sheba Medical Center em Israel. É um pioneiro fundamental na cirurgia urológica robótica e laparoscópica. Especializa-se no tratamento de cancros complexos do rim, próstata e bexiga. O Dr. Dotan lidera a Sociedade Israelita de Uro-Oncologia e possui um doutoramento em Genética.

• Concluiu uma bolsa de especialização em uro-oncologia no Memorial Sloan Kettering em Nova Iorque.
• Realiza nefrectomias radicais robóticas e prostatectomias robóticas da Vinci.
• Autor de mais de 50 publicações científicas sobre tratamentos avançados de cancro urológico.
• Trabalha no Sheba Medical Center, classificado como o 7.º melhor hospital do mundo pela Newsweek.